Graft Polymer (UK) PLC (GB:GPL) has released an update.
Graft Polymer (UK) PLC has partnered with Eurofins Discovery to commence pharmacology testing on a new aminoindane series aimed at treating trauma-related mental health issues like PTSD. This critical phase in their joint pre-clinical program with Awakn Life Sciences Corp promises to explore innovative therapeutic pathways by targeting key neurotransmitters. The company’s focus is on improving mental health treatments and the recent developments signal a significant advancement in their research efforts.
For further insights into GB:GPL stock, check out TipRanks’ Stock Analysis page.
